Ovarian cancer: natural history and metastatic pattern.

作者: A Amadori , E Sansoni , D Amadori

DOI:

关键词:

摘要: Ovarian cancer begins at a molecular level, however to date, our knowledge of genetic changes and mechanisms ovarian tumorigenesis is limited. The natural history may depend on different anatomo-clinical biological factors. In the life cancers stage, histology, tumor grade, age patient gene abnormalities, both oncogenes (c-myc, H-ra, new) oncosuppressor genes (p53, in particular), DNA ploidy steroid receptor status have important prognostic significance. Residual disease, when less than 1 cm, another factor, being significantly associated survival and, progression free, improvement survival. low stage (Stage IA, IB, IAII,IBII,IC,IIA,IIB,IIC), adjuvant treatment seems not influence Disease Free Survival (DFS) or Overall (OS) exception this rule cisplatin regimen assessed, as it can highly reduce relapse rate while influenced. disseminate, primarily by continuity. Lymphatic dissemination pelvic para-aortic lymph nodes (40% patients III-IV disease) well peritoneum common. At time diagnosis, bone brain metastases are rarely present their presence related histology grading tumor.

参考文章(9)
Randall D. Hightower, Hoa N. Nguyen, Hervy E. Averette, William Hoskins, Terry Harrison, Albert Steren, National survey of ovarian carcinoma IV: Patterns of care and related survival for older patients Cancer. ,vol. 73, pp. 377- 383 ,(1994) , 10.1002/1097-0142(19940115)73:2<377::AID-CNCR2820730223>3.0.CO;2-#
Kristján Sigurdsson, Per Alm, Bo Gullberg, Prognostic factors in malignant epithelial ovarian tumors Gynecologic Oncology. ,vol. 15, pp. 370- 380 ,(1983) , 10.1016/0090-8258(83)90055-0
D. J. Zhou, N. Gonzalez-Cadavid, H. Ahuja, H. Battifora, G. E. Moore, M. J. Cline, A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas Cancer. ,vol. 62, pp. 1573- 1576 ,(1988) , 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M
Jacobus Pfisterer, Friedrich Kommoss, Willi Sauerbrei, Heike Renz, Andreas Du Bois, Marion Kiechle-Schwarz, Albrecht Pfleiderer, Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. ,vol. 74, pp. 2509- 2515 ,(1994) , 10.1002/1097-0142(19941101)74:9<2509::AID-CNCR2820740919>3.0.CO;2-F
Robert C. Young, Leslie A. Walton, Susan S. Ellenberg, Howard D. Homesley, George D. Wilbanks, David G. Decker, Alexander Miller, Robert Park, Francis Major, Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. The New England Journal of Medicine. ,vol. 322, pp. 1021- 1027 ,(1990) , 10.1056/NEJM199004123221501
Jacques Dauplat, Neville F. Hacker, Roberta K. Nieberg, Jonathan S. Berek, Thanne P. Rose, Satoru Sagae, Distant metastases in epithelial ovarian carcinoma Cancer. ,vol. 60, pp. 1561- 1566 ,(1987) , 10.1002/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V
Jorge E. Filmus, Ronald N. Buick, Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary. Cancer Research. ,vol. 45, pp. 4468- 4472 ,(1985)
Nap M, Rodenburg Cj, Fleuren Gj, Koelma Ia, Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome. Archives of Pathology & Laboratory Medicine. ,vol. 112, pp. 151- 154 ,(1988)